Wir sind mit live! Mehr erfahren
WVE-Symbol

Wave Life Sciences

3,13 USD
-0,06
1,88 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
3,11
-0,02
0,64 %
1 Tag
-1,88 %
5 Tage
-9,54 %
1 Monat
-30,6 %
3 Monate
-44,8 %
6 Monate
-57,24 %
Seit Jahresbeginn
-80,38 %
1 Jahr
-60,23 %
5 Jahre
-32,4 %
10 Jahre
-89,23 %
 

Profil: WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Mitarbeiter: 317

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 28,6 %
Neutral 61,9 %
Negativ 9,5 %
Neutral
GlobeNewsWire
vor 3 Tagen
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in the “RNA Medicines: Next-Generation RNA Therapeutics” panel at Chardan's 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026 at 9:45 a.m. ET.
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference
Neutral
GlobeNewsWire
vor 15 Tagen
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Neutral
GlobeNewsWire
vor 16 Tagen
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
Positiv
Zacks Investment Research
vor 18 Tagen
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Neutral
GlobeNewsWire
vor 23 Tagen
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Neutral
GlobeNewsWire
vor 24 Tagen
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Positiv
Market Watch
vor 25 Tagen
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
These beaten-down stocks could bounce back in January, if history is any guide
Neutral
GlobeNewsWire
letzten Monat
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Positiv
24/7 Wall Street
vor 2 Monaten
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Neutral
Seeking Alpha
vor 2 Monaten
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Kursdiagramme mit Lightweight Charts™ umgesetzt